Metabolic Reprogramming Is Required for Myofibroblast Contractility and Differentiation.

Area of Science:

• Cell Biology
• Molecular Biology
• Bioenergetics

Background:

• Myofibroblast contraction is vital for tissue repair and fibrosis.
• Cellular contraction requires energy (ATP) produced via mitochondria or glycolysis.
• The bioenergetic adaptations of myofibroblasts are not fully understood.

Purpose of the Study:

• To investigate the metabolic reprogramming of myofibroblasts.
• To explore the role of mitochondrial biogenesis and glycolysis in myofibroblast contraction.
• To elucidate the signaling pathways involved in TGF-β1-induced myofibroblast activation.

Main Methods:

• Treatment of myofibroblasts with transforming growth factor β1 (TGF-β1).
• Analysis of mitochondrial biogenesis and aerobic glycolysis.
• Inhibition of the p38 mitogen-activated protein kinase (MAPK) pathway.
• Genetic or pharmacologic blockade of mitochondrial function or glycolysis.

Main Results:

• TGF-β1 induces mitochondrial biogenesis and aerobic glycolysis.
• p38 MAPK pathway activation is essential for this metabolic reprogramming.
• Inhibition of p38 MAPK, mitochondrial biogenesis, or glycolysis reduces myofibroblast contraction.
• Specific TGF-β1-induced gene expression (α-smooth muscle actin, collagen α-2(I)) is dependent on metabolic reprogramming.

Conclusions:

• TGF-β1-induced metabolic reprogramming is critical for myofibroblast contraction.
• The p38 MAPK pathway mediates TGF-β1's effects on myofibroblast bioenergetics.
• Targeting myofibroblast metabolism offers potential therapeutic strategies for fibrotic diseases.